BACKGROUND AND PURPOSE: Recent clinical data suggest beneficial effects of ivabradine, a specific heart rate (HR)-lowering drug, in heart failure patients. However, the mechanisms responsible for these effects have not been completely clarified. Thus, we investigated functional/molecular changes in I(f), the specific target of ivabradine, in the failing atrial and ventricular myocytes where this current is up-regulated as a consequence of maladaptive remodelling. EXPERIMENTAL APPROACH: We investigated the effects of ivabradine (IVA; 10 mg·kg(-1) ·day(-1) for 90 days) on electrophysiological remodelling in left atrial (LA), left ventricular (LV) and right ventricular (RV) myocytes from post-mycardial infarcted (MI) rats, with sham-operated (sham or sham + IVA) rats as controls. I(f) current was measured by patch-clamp; hyperpolarization-activated cyclic nucleotide-gated (HCN) channel isoforms and microRNA (miRNA-1 and miR-133) expression were evaluated by reverse transcription quantitative PCR. KEY RESULTS: Maximal specific conductance of I(f) was increased in MI, versus sham, in LV (P < 0.01) and LA myocytes (P < 0.05). Ivabradine reduced HR in both MI and sham rats (P < 0.05). In MI + IVA, I(f) overexpression was attenuated and HCN4 transcription reduced by 66% and 54% in LV and RV tissue, respectively, versus MI rats (all P < 0.05). miR-1 and miR-133, which modulate post-transcriptional expression of HCN2 and HCN4 genes, were significantly increased in myocytes from MI + IVA. CONCLUSION AND IMPLICATION: The beneficial effects of ivabradine may be due to the reversal of electrophysiological cardiac remodelling in post-MI rats by reduction of functional overexpression of HCN channels. This is attributable to transcriptional and post-transcriptional mechanisms.
BACKGROUND AND PURPOSE: Recent clinical data suggest beneficial effects of ivabradine, a specific heart rate (HR)-lowering drug, in heart failurepatients. However, the mechanisms responsible for these effects have not been completely clarified. Thus, we investigated functional/molecular changes in I(f), the specific target of ivabradine, in the failing atrial and ventricular myocytes where this current is up-regulated as a consequence of maladaptive remodelling. EXPERIMENTAL APPROACH: We investigated the effects of ivabradine (IVA; 10 mg·kg(-1) ·day(-1) for 90 days) on electrophysiological remodelling in left atrial (LA), left ventricular (LV) and right ventricular (RV) myocytes from post-mycardial infarcted (MI) rats, with sham-operated (sham or sham + IVA) rats as controls. I(f) current was measured by patch-clamp; hyperpolarization-activated cyclic nucleotide-gated (HCN) channel isoforms and microRNA (miRNA-1 and miR-133) expression were evaluated by reverse transcription quantitative PCR. KEY RESULTS: Maximal specific conductance of I(f) was increased in MI, versus sham, in LV (P < 0.01) and LA myocytes (P < 0.05). Ivabradine reduced HR in both MI and sham rats (P < 0.05). In MI + IVA, I(f) overexpression was attenuated and HCN4 transcription reduced by 66% and 54% in LV and RV tissue, respectively, versus MI rats (all P < 0.05). miR-1 and miR-133, which modulate post-transcriptional expression of HCN2 and HCN4 genes, were significantly increased in myocytes from MI + IVA. CONCLUSION AND IMPLICATION: The beneficial effects of ivabradine may be due to the reversal of electrophysiological cardiac remodelling in post-MI rats by reduction of functional overexpression of HCN channels. This is attributable to transcriptional and post-transcriptional mechanisms.
Authors: Yuri D'Alessandra; Paolo Devanna; Federica Limana; Stefania Straino; Anna Di Carlo; Paola G Brambilla; Mara Rubino; Maria Cristina Carena; Liana Spazzafumo; Marco De Simone; Barbara Micheli; Paolo Biglioli; Felice Achilli; Fabio Martelli; Stefano Maggiolini; Giancarlo Marenzi; Giulio Pompilio; Maurizio C Capogrossi Journal: Eur Heart J Date: 2010-06-09 Impact factor: 29.983
Authors: Paul Mulder; Stephane Barbier; Abdeslam Chagraoui; Vincent Richard; Jean Paul Henry; Françoise Lallemand; Sylvanie Renet; Guy Lerebours; Florence Mahlberg-Gaudin; Christian Thuillez Journal: Circulation Date: 2004-02-23 Impact factor: 29.690
Authors: E Cerbai; L Sartiani; P DePaoli; R Pino; M Maccherini; F Bizzarri; F DiCiolla; G Davoli; G Sani; A Mugelli Journal: J Mol Cell Cardiol Date: 2001-03 Impact factor: 5.000
Authors: Kevin W Swan; Bryant M Song; Allen L Chen; Travis J Chen; Ryan A Chan; Bradley T Guidry; Prasad V G Katakam; Edmund K Kerut; Thomas D Giles; Philip J Kadowitz Journal: Am J Physiol Heart Circ Physiol Date: 2017-06-30 Impact factor: 4.733
Authors: Bo Hyun Kim; Kyoung Im Cho; Seong Man Kim; Nari Kim; Jin Han; Jee Yeon Kim; In Ju Kim Journal: Heart Vessels Date: 2012-11-11 Impact factor: 2.037
Authors: Benjamin Hackl; Peter Lukacs; Janine Ebner; Krisztina Pesti; Nicholas Haechl; Mátyás C Földi; Elena Lilliu; Klaus Schicker; Helmut Kubista; Anna Stary-Weinzinger; Karlheinz Hilber; Arpad Mike; Hannes Todt; Xaver Koenig Journal: Front Pharmacol Date: 2022-05-02 Impact factor: 5.988